Hemostasis. Learning objectives Dr. Mária Dux. Components: blood vessel wall thrombocytes (platelets) plasma proteins

Similar documents
Blood clotting. Subsequent covalent cross-linking of fibrin by a transglutaminase (factor XIII) further stabilizes the thrombus.

Primary Exam Physiology lecture 5. Haemostasis

This slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion

Ch. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma

Part IV Antithrombotics, Anticoagulants and Fibrinolytics

Topics of today lectures: Hemostasis

UNIT VI. Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav. Copyright 2011 by Saunders, an imprint of Elsevier Inc.

Blood coagulation and fibrinolysis. Blood clotting (HAP unit 5 th )

-Hashim ahmed is the one who wrote this sheet. I just edited it according to our record.

PHM142 Lecture 4: Platelets + Endothelial Cells

Hemostasis and. Blood Coagulation

Anatomy and Physiology

Chapter 19. Hemostasis

Hemostasis and Thrombosis

Hemostasis. Coagulation vs anticoagulation

Physiology of. The Blood hemostasis. By prof. Israa f. jaafar

Bleeding and Haemostasis. Saman W.Boskani HDD, FIBMS Maxillofacial Surgeon

Introduction to coagulation and laboratory tests

Moath Darweesh. Omar Sami. Saleem Khreisha. 1 P a g e

Hemostasis. Clo)ng factors and Coagula4on NORMAL COAGULATION. Overview of blood coagula4on. The Cascade Theory 5/1/12. Clot

Oral Anticoagulant Drugs

Page 1 of 6 THROMBOCYTES

Anticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT

WHITE PAPERS PRESENTATION VIDEO DOCUMENTATION EXPERIMENT WO NDCLOT. The WoundClot Principals for Effective Bleeding Control PRESENTATION

Diagnosis of hypercoagulability is by. Molecular markers

Hemostasis and fibrinolysis the hemostatic balance

Thrombosis. Jeffrey Jhang, M.D.

Hemostasis Haemostasis means prevention of blood loss from blood vessels.

Chapter 19 Blood Lecture Outline

Outline Anti-coagulant and anti-thrombotic drugs Haemostasis and Thrombosis Year 3 Dentistry

Chapter 1. General introduction

Chapter 1 Introduction

Bleeding Disorders. Dr. Mazen Fawzi Done by Saja M. Al-Neaumy Noor A Mohammad Noor A Joseph Joseph

PHASES OF HAEMOSTASIS

Hemostasis Haemostasis means prevention of blood loss from blood vessels.

Coagulation Disorders. Dr. Muhammad Shamim Assistant Professor, BMU

Coagulation an Overview Dr.Abdolreza Abdolr Afrasiabi Thal assem a & Heamophili hilia G ene i tic R esearc C en er Shiraz Medical Medic University

What are blood clots?

Chapter 19 Cardiovascular System Blood: Functions. Plasma

Coagulation Pathway and Physiology

Chapter 3. Haemostatic abnormalities in patients with liver disease

Hemodynamic Disorders, Thromboembolic Disease, and Shock

L iter diagnostico di laboratorio nelle coagulopatie congenite emorragiche

Platelet-fibrin clot. 50Kd STEMI. Abciximab. Video of a IIb/IIIa inhibitor in action. Unstable Angina and non-stsegment

Review Article Sri Lanka Dental Journal 2016; 46(01) 05-13

4/23/2009. September 15, 2008

WBCs production(leucopoiesis):

Coagulation Pathway and Physiology

ACQUIRED COAGULATION ABNORMALITIES

Blood (II) Huawei Liang, PhD

Hemodynamics. Objectives. Filtration across the endothelium 1/17/2017. K[(P cap - P int )-σ(π cap π int )]

THROMBOTIC DISORDERS: The Final Frontier

Haemostasis & Coagulation disorders Objectives:

Disseminated Intravascular Coagulation. M.Bahmanpour MD Assistant professor IUMS

BIOH122 Human Biological Science 2

ANTICOAGULANTS & FIBRINOLYTIC AGENTS Chapter 34

Blood (5600 ml "8%" of B.W.) RBCs (Erythrocytes)

Hemodynamic Disorders, Thrombosis, and Shock. Richard A. McPherson, M.D.

SELECTED READINGS ORAL AND MAXILLOFACIAL SURGERY HEMOSTATIS: A CLINICAL REVIEW OF PHYSIOLOGY, PATHOLOGY, PHARMACOLOGY, AND PERI-OPERATIVE MANAGEMENT

Dr. MUBARAK ABDELRAHMAN MD PEDIATRICS AND CHILD HEALTH Assistant Professor FACULTY OF MEDICINE -JAZAN

Blood Lecture Test Questions Set 2 Summer 2012

HEME 10 Bleeding Disorders

Chapter 14. Blood. Blood Volume. Blood Composition. Blood

Dental Management of Patients with Bleeding Disorders

Bleeding Disorders HOPE Maram Al-anbar

Blood platelets play important role in coagulation.

Coagula2on or blood clo;ng (secondary hemostasis)

INFLAMMATION & REPAIR

Chapter 11. Lecture and Animation Outline

Approach To A Bleeding Patient

Agent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes ~ 100 units Heparin neutralization in ~ 5 min

Agents for Peripheral Vascular Disease & Thrombosis

Agents for Peripheral Vascular Disease & Thrombosis

Hemostasis and Thrombosis 2nd Edition

Boards and Beyond: Hematology

Prothrombin Complex Concentrate- Octaplex. Octaplex

Instruments smart solutions & service IGZ Instruments AG Räffelstrasse 32 CH 8045 Zürich

Approach to bleeding

Pathology note 8 BLEEDING DISORDER

Y. Helen Zhang, MD Andy Nguyen, MD 10/28/2012

Vol. 25, No. 9 September Angell Memorial Animal Hospital Boston, Massachusetts Lillian I. Good, DVM Ann Marie Manning, DVM, DACVECC

Spontaneous intracerebral hemorrhage due to coagulation disorders

General approach to the investigation of haemostasis. Jan Gert Nel Dept. of Haematology University of Pretoria 2013

We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors

Blood. Plasma. The liquid part of blood is called plasma. 1. Pale yellow fluid; forms more than half the blood volume.

Bleeding Disorders: (Hemorrhagic Diatheses) Tests used to evaluate different aspects of hemostasis are the following:

TOO MUCH TIME. Cell. Cell. Transport System of the Body: O 2 / Energy. Nutrients Waste O 2 CO 2. Source. External environment: Sink.

Perioperative Treatment of the Patient Taking Anticoagulation Medication

TOO MUCH TIME. Cardiovascular System: Blood. Cell. Cell. Transport System of the Body: O 2 / Energy. Nutrients Waste O 2 CO 2.

Chapter 19: Cardiovascular System: Blood

10. Which of the following immune cell is unable to phagocytose (a) neutrophils (b) eosinophils (c) macrophages (d) T-cells (e) monocytes

Chapter 19 Blood. Functions of blood:

DRUGS USED IN COAGULATION DISORDERS

"DENTAL MANAGEMENT OF A PATIENT TAKING ANTICOAGULANTS"

M B Garvey. University of Toronto

Razvana Akbar Anticoagulation Pharmacist LTH

Hemostasis and Blood Forming Organs

Thursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III

HAEMORRHAGIA Bleeding

Inherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD

Transcription:

Hemostasis Learning objectives 14-16 Dr. Mária Dux Components: blood vessel wall thrombocytes (platelets) plasma proteins Hemostatic balance! procoagulating activity anticoagulating activity 1

Thrombocytes Colony Forming Unit-Megakaryocytes Thrombopoietin (glycoprotein): liver, kidney megakaryocyte thrombopoietin thrombopoietin platelets Thrombopoietin in plasma binds to receptors on the surface of circulating platelets; the remaining, unbound thrombopoietin in plasma is available to promote megakaryocyte proliferation. Thus, when the platelet count drops, increased plasma levels of free thrombopoietin stimulate megakaryocytes. Thrombocytes 150 000-300 000/µl blood Size: 1-3 µm Lifespan: 5-8 days Morphology: No nucleus Surface factors (glycoproteins - Integrin) Actin-Myosin Granules dense granules (ADP, serotonin, adrenaline) α-granules (proteins - clotting factors) lysosomes (enzymes) Mitochondria Glycogen 2

Ultrastructure of platelets Adhesion molecules (Integrins) (Ca 2+ ) actin, myosin α2-antiplasmin lysosomes VWF = von Willebrand factor Hemostasis Primary hemostasis local vasoconstriction plug formation Secondary hemostasis blood coagulation WHITE thrombus RED thrombus + defence against infection tissue repair 3

Vasoconstriction slows down the bleeding: 1) Response of vascular smooth muscle to injury. Activation of vasomotor nerves. Vasoconstrictors released by activated thrombocytes. (Thromboxane A 2, serotonin, adrenalin) 2) Mechanical compression: - damaged elastic fibres - blood in the extravascular space Short lasting effect! Formation of thrombocyte plug: 1. Adhesion of thrombocytes to injured blood vessel wall - Hydrodynamic margination - Adhesion of thrombocytes blood vessel wall endothelium Platelets exposure of collagen fibers to blood von Willebrand factor (glycoprotein) damaged endothel (platelets) 4

Formation of thrombocyte plug: 1. Adhesion of thrombocytes to injured blood vessel wall 2. Activation of thrombocytes Intracellular signal transduction Changes in the structure of thrombocytes Exocytosis (release of stored substances) resting activated Activation of thrombocytes thromboxane A 2 (TXA 2 ) ADP serotonin adrenalin INTACT ENDOTHELIUM contact with collagen TXA 2 thrombin [Ca 2+ ] adenylyl cyclase prostacyclin camp camp, cgmp Ca-ATPase free Ca structural changes exocytosis exposition of GP IIb/IIIa THROMBOCYTE NO cgmp nitric oxide 5

Formation of thrombocyte plug: 1. Adhesion of thrombocytes to injured blood vessel wall 2. Activation of thrombocytes 3. Aggregation of thrombocytes blood vessel wall endothelium Platelets von Willebrand factor Bleeding time (Ivy s method): 3-5 min Acetylsalicylic acid Aspirin causes an irreversible inhibition of cyclooxygenase (COX). Inhibition of platelet aggregation 6

Secondary hemostasis Coagulation factors: Enzymes: serine proteases, transglutaminase (Factor XIII) Cofactors (Factor V,VIII) Ca 2+ + Vitamin K Surface: subendothelial collagenmatrix membrane of the thrombocytes (phospholipid) Coagulation factors cascade Factor Factor a 7

Vitamin K (phylloquinone ) (in green vegetables) Serves as a cofactor in the γ-carboxylation of glutamic acid residues (post-translational processing) on various proteins concerned with blood clotting. Vitamine K dependent factors - II, VII, IX, X, Protein-C, Protein-S (inhibition!) γ - carboxyglutamic acid binds Ca 2+ Tissue Factor Pathway Inhibitor Membrane protein (blood vessel wall) (activated endothel and makrophages) Extrinsic tissue injury Ca ++ tissue factor Prekallikrein Intrinsic negatively charged surface Kininogen It is not the main pathway of activation BUT: 1. It has a positive feedback on the cascade. 2. It is important in fibrinolysis, tissue repair, complement activation. 3. It can be activated on the surface of artificial heart valves. Formation of fibrin Peptides Fibrin polymer 8

Complexes of blood coagulation VIIa-PPL-Ca 2+ complex IXa-VIIIa-PPL-Ca 2+ complex Xa-Va-PPL-Ca 2+ complex Xa IXa X Ca 2+ VIIIa Platelet phospholipid Platelet phospholipid Ca 2+ : calcium PT: prothrombin Thr: thrombin Tissue Factor Pathway Inhibitor Membrane protein (blood vessel wall) (activated endothel and makrophages) Extrinsic tissue injury Ca ++ tissue factor Prekallikrein Intrinsic negatively charged surface Kininogen It is not the main pathway of activation BUT: 1. It has a positive feedback on the cascade. 2. It is important in fibrinolysis, tissue repair, complement activation. 3. It can be activated on the surface of artificial heart valves. Formation of fibrin Peptides Fibrin polymer 9

VIIIa Va FIBRIN XIIIa XI XIa PROTEIN C PROTEIN Ca Ca ACTIVATION + tissue repair defence against infection Formation of fibrin weak bonds formed through noncovalent bindings strong covalent bonds factor XIIIa (fibrin-stabilizing factor) - transglutaminase 10

RETRACTION (within a few hours): a compact red clot is formed (actin/myosin attached to fibrin fibres), clear yellowish fluid ( serum coagulation factor-free plasma) is squeezed out. serum + coagulation factors = plasma What is Factor III (Thromboplastin)??? The term thromboplastin was originally assigned to the putative activator of factor II (prothrombin). In light of our present knowledge, however, it is the Xa-Va-PPL-Ca 2+ complex that should be designed as thromboplastin. Since the tissue factor was earlier thought to be directly responsible for the conversion of prothrombin to thrombin, the tissue factor was called tissue thromboplastin. Because of the ambiguities, the terms Factor III and Thromboplastin are best avoided. 11

Anti-hemostatic mechanisms Inactivation of thrombin: Antithrombin (III)/ heparin produced by the liver serine protease inhibitor heparin acts as cofactor Protein C/Thrombomodulin Thrombomodulin of the undamaged endothel binds thrombin. The thrombomodulin - thrombin complex activates protein-c. Protein-Ca inactivates factors Va and VIIIa. Fibrinolytic system Tissue-type plasminogen activator (endothelium) Fibrin Plasminogen Plasmin Streptokinase Urokinase Factor XIIa short fragmets α 2 -antiplasmin of thrombocytes inhibits the activation of plasminogen. 12

Anticoagulants: In vivo: Heparin Vitamin K antagonists Dicumarol, Warfarin Selective Xa inhibitor (inhibiting thrombin formation) In vitro: Heparin Binding of Ca 2+ Na-oxalate Na-citrate EDTA Tests for coagulation disorders Prothrombin time (PT) assesses the extrinsic + common pathways of coagulation within 20 sec Prothrombin index (Quick) 75 125% Partial thromboplastin time (PTT) assesses the intrinsic + common pathways of coagulation within 45 sec INR (International normalized ratio) 0.8-1.2 INR = ( PT test PT normal ) ISI ISI (International Sensitivity Index) 13

Hemorrhagic disorders 1) Vascular disorders (increased capillary fragility) 2) Platelet disorders spontaneous bleeding on the skin and mucous membranes purpura 3) Coagulation disorders Bleeding occurs following injury and does not stop easily. Bleeding occurs in joints. Genetic deficiency of coagulation factors: VIII Hemophilia A IX Hemophilia B - royal disease Queen Victoria (1819 1901) and her family Blood can change the course of history Lannoy, Hermans 2010 Haemopilia 14